Global Axial Spondyloarthritis (axSpA) Market 2023-2029

Global Axial Spondyloarthritis (axSpA) Market 2023-2029

Axial spondyloarthritis (axSpA) is a type of inflammatory arthritis that primarily affects the spine, but it can also affect other joints and organs such as the eyes, skin, and gut. It is a chronic condition that can cause pain, stiffness, and loss of mobility. Early diagnosis and treatment of axial spondyloarthritis are essential to control the symptoms and prevent complications. While there is no cure for axial spondyloarthritis, effective treatment can help manage the symptoms and improve quality of life. The global axial spondyloarthritis market size is projected to grow by USD 1.2 billion from 2023 to 2029, registering a CAGR of 7.84 percent, according to the latest market data.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global axial spondyloarthritis market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the commercialized therapies, indication, and region. The global market for axial spondyloarthritis can be segmented by commercialized therapies: anti-tumor necrosis factor therapy, anti-interleukin 17 therapy, anti-janus kinase therapy. Globally, the anti-tumor necrosis factor therapy segment made up the largest share of the axial spondyloarthritis market. Axial spondyloarthritis market is further segmented by indication: ankylosing spondylitis, non-radiographic axial spondyloarthritis (nr-axSpA). The ankylosing spondylitis segment captured the largest share of the market in 2022. Based on region, the axial spondyloarthritis market is segmented into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. According to the research, North America had the largest share in the global axial spondyloarthritis market.

Market Segmentation

By commercialized therapies: anti-tumor necrosis factor therapy, anti-interleukin 17 therapy, anti-janus kinase therapy

By indication: ankylosing spondylitis, non-radiographic axial spondyloarthritis (nr-axSpA)

By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The global axial spondyloarthritis market report offers detailed information on several market vendors, including Pfizer Inc., Johnson & Johnson Services, Inc., Novartis International AG, UCB S.A., Eli Lilly and Company, Kyowa Kirin Co., Ltd., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Merck & Co., Inc., Takeda Pharmaceutical Company Limited, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.



Scope of the Report

• To analyze and forecast the market size of the global axial spondyloarthritis market.
• To classify and forecast the global axial spondyloarthritis market based on commercialized therapies, indication, region.
• To identify drivers and challenges for the global axial spondyloarthritis market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global axial spondyloarthritis market.
• To identify and analyze the profile of leading players operating in the global axial spondyloarthritis market.

• Gain a reliable outlook of the global axial spondyloarthritis market forecasts from 2023 to 2029 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.